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or older and were diagnosed as diabetes during July 2008 – June 2011 with 
receiving glucose lowering agent were included. All included patients were 
categorized into thiazolidinedione (TZDs) and non-TZDs groups. PS were 
estimated by conventional and time-specific approaches. In the time-specific 
approach, PS was separately estimated into 3 groups by calendar time. The pair 
t-test was used to compare the PS of both approaches. Patients were matched 
using caliper nearest neighbor matching with no replacement. The multivariate 
Cox proportional hazard model was used to determine the adjusted hazard ratio 
of cardiovascular hospitalizations of TZDs and non-TZDs in matched cohorts. 
RESULTS: A total of 2165 patients were included in this study. Patients were on 
average 58.8 ± 12.7 years of age with 44.5% of male. The average conventional PS 
was 0.198, which was significantly lower than the average time-specific PS of 
0.209.For CVD-related hospitalization, the adjusted hazard ratio (HR) of 
conventional PS-matched cohort was 1.05 (95% confidence interval (CI); 0.38 – 
2.89), while that of time specific PS-matched cohort was 1.12 (95%CI; 0.43 – 2.92). 
CONCLUSIONS: Propensity scores estimated by conventional and time-specific 
approaches were different. The different PS approaches could lead to different 
estimates of treatment effects. 
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OBJECTIVES: Proportion of days covered (PDC) has gained increased popularity 
as a key measure of medication adherence. The Centers for Medicare and 
Medicaid Services (CMS) now uses PDC to measure medication adherence for 
quality improvement in Medicare Part D. PDC can be calculated at various drug 
classification levels such as a particular drug (e.g. metformin, glipizide) or a 
broad therapeutic class (e.g. all oral anti-diabetes drugs). The objective of this 
analysis is to show how PDC calculations at different drug levels can result in 
varied adherence estimates. METHODS: The analysis used a sample of claims 
data for all oral anti-diabetes drugs from a national pharmacy and defined drug 
levels using Medispan’s Generic Product Identifiers (GPI). Three methods were 
used to calculate PDCs. In method 1, PDC was computed for each GPI6, and then 
rolled up to the patient level using weighted averages. In methods 2 and 3, PDC 
was calculated for the entire therapeutic area of oral anti-diabetes drugs. Method 
2 used GPI6, and method 3 used GPI10 to determine the drugs; any medication 
overlaps between different drugs were ignored to avoid double counting and any 
medication overlaps within the same drug were pushed out to make adjustment 
in the days covered. RESULTS: PDC was 0.64 for method 1 and 0.69 for both 
methods 2 and 3. Compared to method 1, PDCs from method 2 and 3 were 5% 
higher (N= 188,121, P-value < 0.0001). Among patients with 1 or more distinct 
GPI6s, the difference was even bigger – PDCs from method 2 and 3 were 10% 
higher (N= 90,064, P-value< 0.0001) than that from method 1 (0.75 vs. 0.65). 
CONCLUSIONS: PDCs at varied drug levels could lead to different medication 
adherence estimates and impact conclusions about medication adherence, 
especially for patients who switch drugs within a drug class or use combination 
therapies.  
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OBJECTIVES: In recent years, addiction and problematic use of prescription 
opioid analgesic medications has increased. Using medical and pharmacy claims 
data, the purpose of this study was to compare two methods of characterizing 
problematic opioid use among a commercially insured chronic pain patient 
population. METHODS: A national managed care organization provided medical 
and pharmacy data for individuals with chronic pain and an opioid prescription 
fill during calendar years 2009-2011. Members were placed into one of two 
problematic opioid use groups based on the following criteria: “Doctor Shopping” 
(n = 552), defined as the filling of opioid prescriptions from five or more different 
prescribers within 12 months; and “Rapid Dose Escalation” (n = 741), defined as a 
50% increase in opioid dose in the first 3 months of treatment, or 100% increase 
in dose during the 12-month post-period. Groups were compared on the patient 
characteristics of age, gender, Charlson Comorbidity, and region of residence, 
and on the change in health care service utilization and expenditure over an 18-
month period. RESULTS: Members in the Doctor Shopping group were 
significantly more likely to be female than members in the Rapid Dose Escalation 
group (57.1% vs. 51.3%; p < .025), and also incurred significantly greater increases 
in emergency room charges ($810 vs. $265; p < 0.005). The two groups did not 
differ on any remaining demographics or service utilization estimates, including 
inpatient admissions, days, and costs; office visits and costs; outpatient hospital 
visits and costs; total prescription and opioid-specific costs and days’ supply; 
total health care costs; and the Charlson (p’s > 05). CONCLUSIONS: Results 
revealed only slight differences in demographic makeup and health care 
expenditure across the two problematic opioid use groups, suggesting the 
successful identification of a single, homogenous group. The use of either 
method alone would likely underestimate the prevalence of this burgeoning 
problem.  
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OBJECTIVES: Computerized medication alerts, such as drug-drug interaction 
(DDI) warnings, are intended to improve decision-making at the time of 
prescribing and enhance patient safety. The alert interface influences 
prescribers’ perceptions of warnings, but the interface design of DDI alerts is 
largely unstudied. The objectives were to conduct a simulation study to evaluate 
whether design changes reduce medication errors and improve prescribing 
efficiency. METHODS: We conducted a counterbalanced crossover study with 
outpatient prescribers to evaluate two different DDI alert designs. Redesigned 
alerts incorporated human factors principles such as guidelines for warning 
design; the original alert design served as the control. During the simulation, 
Veterans Affairs outpatient prescribers completed three fictional patient cases 
using both the original and the redesigned alerts. We used six clinically relevant 
DDI alerts of varying severity. Prior to data collection, each DDI was assigned 
correct and incorrect actions to evaluate medication errors. The primary 
outcome was medication errors defined as the number of incorrect actions over 
the number of alerts prescribers received. A secondary outcome was prescribing 
efficiency, defined as the time spent reviewing and resolving all alerts within 
one patient case. The original and redesigned alerts were compared using 
McNemar’s test for medication errors and Wilcoxon signed-rank test for 
efficiency. RESULTS: Twenty prescribers (14 physicians, 4 pharmacists, and 2 
nurse practitioners) completed patient cases for both designs. Medication errors 
were significantly reduced with redesigned alerts (27.5%) compared to the 
original alerts (47.4%; p<0.001). Median time spent on redesigned alerts was 52 
seconds compared to 97 seconds for the original alerts (p<0.001), saving 
prescribers 45 seconds per case. CONCLUSIONS: Based on this simulation study, 
incorporating human factor principles into computerized medication alert 
systems may improve prescribing and patient safety. Evaluation of redesigned 
alerts in a clinical setting is needed to understand the effects during actual 
patient care.  
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OBJECTIVES: To assess and compare the functional outcome/recovery of ischemic 
and intracerebral hemorrhage at discharge from hospital, using modified rankin 
scale and barthel index. METHODS: In the present retrospective study, 140 stroke 
patients (110 patients of infarction including patients of Transient Ischemic Attack 
and 30 hemorrhage patients) were enrolled, their medical records studied and were 
compared for risk factors, disability at discharge, groups’ length of stay and 
mortality. Mean scores on both, Modified Rankin Scale (mRS) and Barthel Index (BI) 
were determined at admission and discharge and then compared using paired ttest. 
Ischemic group was also sub-divided into 2 groups on the basis of treatment with 
tissue plasminogen activator (t-PA) and their scores were also compared with same 
test. Good (mRS score <2 and BI score > 60) or poor outcome (mRS score >2 and BI 
score < 60), were distinguished in both the stroke groups using on both scales. 
RESULTS: Ischemic stroke patients had higher mean score on Barthel Index (70.2, 
p=0.0026) and lower mean score on Modified Rankin Scale (2.3, p=0.000) at discharge 
compared to hemorrhage patients (BI score = 36.67 and mRS score = 3.7). 
Hypertension was determined as the most prevalent risk factor in both the stroke 
types. CAD, atrial fibrillation, previous stroke, diabetes mellitus, alcohol were other 
major factors. ~65% ischemic stroke patients were discharged with a good outcome 
whereas only 30% patients in the hemorrhage group were discharged with a good 
outcome. Patients treated with t-PA experienced better outcome than the patients 
managed conservatively. CONCLUSIONS: The results provide evidence of better 
functional outcome and recovery in ischemic stroke patients at discharge and 
greater risk of mortality in patients with intracerebral hemorrhage.  
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OBJECTIVES: Composite endpoints (CEPs) are being used more frequently in 
describing outcomes for trials of drugs in type-2 diabetes. We reviewed the 
literature on CEPs to determine how they have been used to date on currently 
marketed antidiabetics. METHODS: Medline, Embase and Cochrane databases 
and Clinicaltrials.gov were searched for randomized controlled Phase-3 trials of 
currently marketed incretins, which were grouped by class. We sought trials of 
GLP-1 agonists, DPP-4 inhibitors and SGLT-2 inhibitors. CEPs used were identified 
as well as numbers and percentages of patients achieving each, the time of 
measuring the CEPs and the comparison drugs involved in those trials. RESULTS: 
Twelve studies involving 5611 patients provided data. Drug classes included GLP-
1 agonists (exenatide 10 mcg twice daily, exenatide 2 mg weekly, liraglutide 1.2 
mg daily, and liraglutide 1.8 mg daily), DPP-4 inhibitors (sitagliptin 100 mg daily). 
No studies were found in the literature reporting CEPs for SGLT-2 inhibitors. 
Approximately 18% of patients were treated as first line therapy, 55% as second 
line, and 27% as third. Active comparison drugs and background treatments 
included insulin, metformin, sulfonyluyreas, and thiazolidinediones. Eleven 
different CEPs were used (6 with 2 components, 5 with 3 components). All CEPs 
